Senzime Secures First European Hospital Order for its New Next-Generation TetraGraph System
Senzime has secured its first order for the next-generation TetraGraph system from a Swiss hospital, comprising 20 monitors for Q1 2025 delivery with expected revenues of SEK 3 million over three years, including disposable sensors. The system, launched at ANESTHESIOLOGY 2024, features advanced monitoring capabilities including the Level-of-Block Gauge™, Adaptive Intelligence™, and an improved EMG algorithm with 4x higher resolution. The technology aligns with new clinical guidelines requiring quantitative monitoring of neuromuscular blocking drugs used in approximately 100 million surgical procedures annually.
Senzime ha ricevuto il suo primo ordine per il sistema di nuova generazione TetraGraph da un ospedale svizzero, comprendente 20 monitor per consegna nel primo trimestre del 2025, con ricavi previsti di 3 milioni di SEK nei prossimi tre anni, inclusi i sensori monouso. Il sistema, lanciato all' ANESTHESIOLOGY 2024, presenta avanzate capacità di monitoraggio, tra cui il Level-of-Block Gauge™, l'Adaptive Intelligence™ e un algoritmo EMG migliorato con una risoluzione 4 volte superiore. Questa tecnologia si allinea con le nuove linee guida cliniche che richiedono il monitoraggio quantitativo dei farmaci per il blocco neuromuscolare utilizzati in circa 100 milioni di procedure chirurgiche ogni anno.
Senzime ha asegurado su primer pedido para el sistema de próxima generación TetraGraph de un hospital suizo, que comprende 20 monitores para entrega en el primer trimestre de 2025, con ingresos esperados de 3 millones de SEK en tres años, incluyendo sensores desechables. El sistema, lanzado en ANESTHESIOLOGY 2024, cuenta con capacidades de monitoreo avanzadas, incluyendo el Level-of-Block Gauge™, Adaptive Intelligence™ y un algoritmo EMG mejorado con una resolución 4 veces superior. La tecnología se alinea con las nuevas pautas clínicas que requieren un monitoreo cuantitativo de los fármacos bloqueadores neuromusculares utilizados en aproximadamente 100 millones de procedimientos quirúrgicos anualmente.
Senzime는 스위스 병원으로부터 차세대 TetraGraph 시스템에 대한 첫 번째 주문을 확보했습니다. 이 주문은 2025년 1분기에 배송되는 20대의 모니터로 구성되며, 3년 동안 총 300만 SEK의 수익이 예상되며, 일회용 센서도 포함되어 있습니다. ANESTHESIOLOGY 2024에서 출시된 이 시스템은 Level-of-Block Gauge™, Adaptive Intelligence™, 4배 높은 해상도를 가진 향상된 EMG 알고리즘 등 고급 모니터링 기능을 가지고 있습니다. 이 기술은 매년 약 1억 건의 외과 수술에서 사용되는 신경근 차단제의 정량적 모니터링을 요구하는 새로운 임상 가이드라인에 부합합니다.
Senzime a obtenu sa première commande pour le système de nouvelle génération TetraGraph d'un hôpital suisse, comprenant 20 moniteurs pour une livraison au premier trimestre 2025, avec des revenus prévus de 3 millions de SEK sur trois ans, y compris des capteurs jetables. Le système, lancé lors de ANESTHESIOLOGY 2024, propose des capacités de surveillance avancées, y compris le Level-of-Block Gauge™, l'Adaptive Intelligence™ et un algorithme EMG amélioré avec une résolution quatre fois plus élevée. Cette technologie est en accord avec les nouvelles lignes directrices cliniques exigeant un suivi quantitatif des médicaments de blocage neuromusculaire utilisés dans environ 100 millions d'interventions chirurgicales chaque année.
Senzime hat seine erste Bestellung für das nächste Generation TetraGraph System von einem Schweizer Krankenhaus gesichert, das 20 Monitore für die Lieferung im ersten Quartal 2025 umfasst, mit erwarteten Einnahmen von 3 Millionen SEK über die nächsten drei Jahre, einschließlich Einwegsensoren. Das System, das auf der ANESTHESIOLOGY 2024 vorgestellt wurde, bietet fortschrittliche Überwachungsfunktionen, darunter den Level-of-Block Gauge™, Adaptive Intelligence™ und einen verbesserten EMG-Algorithmus mit 4-facher Auflösung. Die Technologie entspricht den neuen klinischen Richtlinien, die eine quantitative Überwachung von neuromuskulären Blockern verlangen, die jährlich in etwa 100 Millionen chirurgischen Eingriffen verwendet werden.
- Secured first European order worth SEK 3 million over 3 years
- Successfully launched next-generation TetraGraph with enhanced features
- Product aligns with new mandatory US and European clinical guidelines
- Technology addresses large market of 100 million surgical procedures annually
- None.
UPPSALA, SWEDEDN / ACCESSWIRE / October 23, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Uppsala, Sweden - Senzime AB announces that it has secured the first order for the just launched next-generation TetraGraph system from a leading Switzerland hospital. The initial order consists of 20 monitors planned for delivery in Q1 2025. Estimated revenues of the initial 3-year term is expected to reach SEK 3 million including deliveries of disposable sensors.
The next-generation TetraGraph system was launched at the ANESTHESIOLOGY (ASA) 2024 conference held in the US on October 18th, 2024. The new TetraGraph is designed to help accelerate alignment to new clinical guidelines of quantitative train-of-four (TOF) monitoring with its proprietary Level-of-Block Gauge™, unique Adaptive Intelligence™ enabling precision-based monitoring, and a new 6th generation EMG algorithm with 4x higher resolution for unprecedented clinical accuracy.
"I am very satisfied with the launch at ASA and the positive response from US and international clinicians. The next-generation TetraGraph was highlighted in opening presentations consisting of leading anesthesiologists and ASA Task Force Members that led the recent publication of guidelines in favor of quantitative neuromuscular monitoring. This first order from Switzerland is a milestone and the start of an exciting commercial phase and I expect the new next-generation TetraGraph to reach new users and lead to continued growth in utilization rates", comments Philip Siberg, CEO of Senzime.
Each year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. These medications paralyze muscles required for breathing, making accurate monitoring during surgery essential for ensuring each patient receives the appropriate dose for a safe and timely recovery.
Senzime markets the TetraGraph portfolio including monitoring solutions used by anesthesiologists in thousands of operating rooms in leading hospitals worldwide. The proprietary technology meets the requirements of the recently published US and European clinical guidelines that is mandating anesthesiologists to use monitors to accurately determine the correct dose of neuromuscular blocking drugs and their antagonists and determine when patients have safely recovered post-surgery.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
About Senzime
Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany.
Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com .
Attachments
Senzime secures first European hospital order for its new next-generation TetraGraph system
SOURCE: Senzime
View the original press release on accesswire.com
FAQ
What is the value of Senzime's (SNZZF) first European order for the next-generation TetraGraph?
When will Senzime (SNZZF) deliver the first European order of next-generation TetraGraph systems?
What are the key features of Senzime's (SNZZF) next-generation TetraGraph system?
